panitumumab,bevacizumab
amgen,takeda,roche
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
ph 3 paradigm trial: folfox-pani v folfox-bev as 1l treatment in ras wt mcrc left-sided tumors treated w/ pani had: os (37.9 v 34.3, hr 0.82) orr (80% v 68%) r0 resection (18% v 11%) not exactly a practice changing study... but no doubt left some thoughts #asco22 
??Medical Oncologist, MSc, PhD. GI/neuroendocrine/GU tumors/breast cancer ??Hospital Universitario UFC-CE, Oncologia D’Or